Scarica l'app Stockscreener
0.6456
7.24%
0.0436
Dopo l'orario di chiusura:
.65
0.0044
+0.68%
Geovax Labs Inc Borsa (GOVX) Ultime notizie
Why Is GOVX Stock Falling Today? - Stocktwits
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences Summit - Yahoo Finance
GeoVax (GOVX) Financial Results: The Available Earnings Metric Delivers a Beat at the Close; Price Move: Shares Move 0.86% DownRevenue Estimate Trend - vinanet.vn
GOVX Stock Became A Hot Biodefense Trade Amid Ebola, Hantavirus Concerns - Stocktwits
GeoVax Labs (GOVX): Armistice Capital and Steven Boyd disclose 4.99% stake - Stock Titan
GeoVax Labs (GOVX) holders report 1.59% stake tied to 118,715 warrants - Stock Titan
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola Outbreak - Yahoo Finance
GeoVax Labs, Inc. (GOVX) holders cap ownership at 4.99% with warrants - Stock Titan
GOVX: GEO-MVA targets a $1.3B vaccine market gap with expedited approval and scalable U.S. supply - TradingView
GeoVax Labs (GOVX) Dips 3.38% to $0.74, Holding Above Key $0.70 SupportDaily Profile - Vinanet
GeoVax Labs (NASDAQ:GOVX): What Could Today’s program progress and financing needs Update Reveal? - Kalkine Media
GeoVax Labs, Inc. (GOVX) Stock Price, News, Quote & History - Yahoo! Finance Canada
GeoVax targets Q4 phase 3 trial for MVA mpox vaccine with EMA expedited pathway - Proactive financial news
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New Phase - Yahoo Finance
GeoVax Labs (GOVX) Dips 2.07% to $0.75 as Biotech Tests Key SupportConversion Trade - dars.gov.et
Jane Street Group discloses 4.3% GeoVax Labs (GOVX) ownership in updated 13G - Stock Titan
Health preparedness key as biological threats evolve - BioProcess International
GOVX Q2 2026 Earnings: Loss Narrower Than Expected Despite No RevenueBasic EPS Analysis - vinanet.vn
GOVX Q2 2026 Earnings: Narrower-than-Expected Loss of $0.97 Per Share Beats Estimates by 67%Peak Earnings Alert - vinanet.vn
GeoVax Completes Key Milestones for GEO-MVA, Paving Way for Phase 3 Trial - citybuzz -
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical Study - Yahoo Finance
GeoVax Highlights Newly Published Independent Research Supporting Broader Filovirus Vaccine Strategies and Strategic Value of Its MVA-Based Vaccine Portfolio - Yahoo Finance
GeoVax Labs (GOVX) Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.97 Per ShareOne-Time Loss Impact - Vinanet
GeoVax Labs Inc (GOVX) Institutional Confidence - TradingKey
GOVX Q2 2026 Earnings: EPS Surprises Positively Despite Revenue AbsenceReturn On Assets - vinanet.vn
GOVX Q2 2026 Earnings: Narrower-than-expected loss highlights cost discipline amid developmental stageRevenue Inflection Point - vinanet.vn
GeoVax Labs (GOVX) Drops 6.82% as Biotech Stock Tests Key Support LevelsTurnaround Stocks - dars.gov.et
GeoVax Labs Inc (GOVX) Valuation: PE, PB & Fair Value Analysis - TradingKey
GeoVax Labs, Inc. 2026 Q2 Financial Report: Earnings, Losses & Key Financial Statements Overview - Minichart
GeoVax Advances GEO-MVA Pivotal Study Amid Strategic Reprioritization - citybuzz -
GeoVax Labs, Inc. Reports Q2 2026 Financial Results and Advances in Immuno-Oncology Programs - Minichart
GEOVAX LABS ($GOVX) Releases Q2 2026 Earnings - Quiver Quantitative
GeoVax Labs Inc reports results for the quarter ended June 30Earnings Summary - TradingView
GeoVax Reports Q2 2026 Net Loss of $4.4 Million - Quiver Quantitative
GeoVax Labs reports Q2 net loss $4.43M, cash ~$3.1M; advances GEO‑MVA pivotal study - TradingView
GeoVax Labs, Inc. 2026: Revenue $0 EPS ($0.97) — 10-Q Summary - TradingView
GeoVax Labs (GOVX) narrows loss but warns on cash runway and Nasdaq risk - Stock Titan
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business Update - TradingView
GeoVax Labs Inc (GOVX) Cash Flow - TradingKey
GeoVax Labs Inc (GOVX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
GeoVax Labs Inc (GOVX) Balance Sheet - TradingKey
GeoVax Labs Inc (GOVX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GOVX Q1 2026 Earnings: Narrowed Loss Beats Estimates Amid No RevenueQuarterly Financial Update - vinanet.vn
GeoVax Labs, Inc. Revenue Breakdown – NASDAQ:GOVX - TradingView
GeoVax Labs (GOVX) Tumbles 13% as Biotech Stock Tests Key Support at $0.69Earnings Breakout Stocks - dars.gov.et
GOVX|GeoVax Labs Inc|Price:0.755|Chg%:+0.024 - TradingKey
GOVX|GeoVax Labs Inc|Price:0.770|Chg%:+0.049 - TradingKey
GeoVax Labs Inc (GOVX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GeoVax Labs Inc (GOVX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
GeoVax Labs Inc (GOVX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
GOVX|GeoVax Labs Inc|Price:0.733|Chg%:-0.107 - TradingKey
GeoVax Labs Inc expected to post a loss of $2.88 a shareEarnings Preview - TradingView
GOVX Q1 2026 Earnings: Narrowed Losses Drive Positive Market ReactionEarnings Decline Risk - Vinanet
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness Strategy - Yahoo Finance
GOVX Q1 2026 Earnings: Narrower Loss Beats Expectations as Biotech Advances PipelineEarnings Stability Report - vinanet.vn
GOVX Q1 2026 Earnings: Narrower-than-Expected Loss Drives Positive Market ReactionReturn On Assets - Vinanet
GeoVax Labs (GOVX) Rallies Nearly 12% as Bulls Approach Key Resistance LevelSingle Stock ETF - vinanet.vn
GOVX stock soars 80%: Retail traders are piling in as Ebola, hantavirus risks resurface - MSN
GeoVax Labs(GOVX) Stock Options Chain | Quotes & News - Moomoo
GeoVax Labs Faces Nasdaq Noncompliance and Listing Risk - The Globe and Mail
GeoVax Labs, Inc. Receives Nasdaq Delisting Notice – Company Plans to Regain Compliance | 8-K Filing July 2026 - Minichart
GeoVax Labs Inc (GOVXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
GEOVAX LABS INC (GOVX) Stock Chart - ChartMill
1.21%
1.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):